Exclusion of Objectionable Microorganisms from Nonsterile Pharmaceuticals, Medical Devices, and Cosmetics

Technical Report No. 67

ISBN: 978-0-939459-70-4
© 2014 Parenteral Drug Association, Inc.
All rights reserved.
The content of this technical report represents a consensus and not necessarily the views of the organizations that employ the team members.
Table of Contents

1.0 INTRODUCTION ........................................... 1
  1.1 Purpose............................................... 1
  1.2 Scope................................................. 1
  1.2.1 Exclusions......................................... 2

2.0 GLOSSARY OF TERMS ....................................... 3

3.0 REGULATORY, COMPENDIAL AND SCIENTIFIC ENVIRONMENT ........................................... 5
  3.1 GMP.................................................... 5
  3.2 Compendial Microbiological Testing................. 5
  3.3 Implications of the Human Microbiome Project.... 7
  3.4 Quality Risk Management.............................. 7

4.0 INDUSTRY BENCHMARKING .................................. 9

5.0 PRODUCT TYPES AND FORMULATION ..................... 11
  5.1 Microbial Risk Evaluation............................ 11
  5.2 Hurdle Technology: Background..................... 12
  5.3 Hurdle Technology in Product Development........ 13
  5.4 Intermediate A w Formulations...................... 15
  5.5 High A w Formulations............................... 15
  5.6 Risk Assessment of the Manufacturing Processes of Pharmaceutical, Medical Device and Cosmetic Ingredients and their Use in Nonsterile Products.. 16
  5.7 Preservative Systems in Nonsterile Pharmaceutical and OTC Drug Products... 18
  5.8 Packaging Considerations for Nonsterile Product Dosage Forms.............. 20
    5.8.1 Package Design, Material, Construction and Function............. 22
    5.8.2 Manner and Site of Application Based on the Package ............ 23
    5.8.3 Frequency and Duration of Product Package Use .................. 24
    5.8.4 Environment Under Which the Product Package is Used and Stored .. 24

6.0 MITIGATING RISK THROUGH PROCESS DESIGN, MANUFACTURING AND PACKAGING OPERATIONS ........................................... 26
  6.1 Manufacturing Process Equipment.................... 26
  6.2 Basic Hygienic Designs of Process Equipment.... 26
  6.3 Preventative Maintenance............................ 27
  6.4 Cleaning and Sanitization Practices ............... 27
    6.4.1 Cleaning In Place................................ 28
    6.4.2 Choosing Detergents................................ 29
    6.4.3 Draining and Drying of Equipment.................. 31
  6.5 Manufacturing Processes and Microbial Content... 31

7.0 LABORATORY TESTING — MICROBIAL ENUMERATION, DETECTION AND IDENTIFICATION ........................................... 33
  7.1 General Testing Requirements ....................... 33
  7.2 Regulatory Testing and their Relationship to Compendial Methods ........... 34
  7.3 Inconsistencies and Contradictions Among USP/NF Monographs .................. 35
  7.4 Laboratory Testing for Microbial Enumeration, Absence of Specified Microorganisms and Microbial Identification.................. 35
    7.4.1 USP/EP/JP Harmonized Chapters <61>, <62>, and <1111> ............. 35
  7.4.2 Chinese Pharmacopoeia Appendix XI J — Microbial Limit Tests ..... 36
  7.4.3 Chapter 23, “Microbiological Methods for Cosmetics,” of the FDA’s BAM ...... 37
  7.4.4 Cosmetics Toiletries & Fragrance Association Methods for Microbial Content and Examination for S. aureus, E. coli and P. aeruginosa ... 38
  7.4.5 ISO Standards.................................... 38
  7.4.6 Microbial Identification.......................... 40
  7.5 Screening for Objectionable Microorganisms........ 41
    7.5.1 Laboratory Management Recommendation to the Quality Unit for Batch Release .. 42
  7.6 Sample Handling, Transportation and Storage.. 43

8.0 CLINICAL CONSIDERATIONS FOR SELECTING ISOLATES FOR ASSESSMENT OF THEIR STATUS AS OBJECTIONABLE OR NOT................. 44
  8.1 Microorganisms Associated with Product Recalls................................. 44
  8.2 Microorganisms Associated with Clinically Significant Infections ........... 44
  8.3 Microorganisms Associated with Outbreak Investigations by the Centers for Disease Control and Prevention.............................. 45
  8.4 Burkholderia cepacia Complex........................ 48
  8.5 Pathogens Listed by Research Organizations, Regulatory Agencies and Authors of Prominent Microbiology Textbooks................. 49

9.0 RISK ASSESSMENT AND MITIGATION ......................... 51
  9.1 Risk-Based Approaches............................... 51
  9.2 Risk Assessment...................................... 51
    9.2.1 Determination of Isolate’s Novelty ............... 51
    9.2.2 Determination of Known Pathogenicity ............ 52
    9.2.3 Assessment of Survivorship....................... 52
    9.2.4 Determination of Product or Container Impact .. 52
9.2.5 Assessment of Quantity or Bioburden .......... 52
9.2.6 Nature of Product ........................................ 52
9.2.7 Route of Administration ............................... 53
9.2.8 Target Patient Population ......................... 53
9.3 Decision Tree ................................................. 54

10.0 CONCLUSIONS ............................................. 56

11.0 REFERENCES .............................................. 57

FIGURES AND TABLES INDEX

| Figure 3.4-1 | Application of Quality Risk Management .......... 8 |
| Figure 5.2-1 | Hurdle Technology ........................................ 12 |
| Table 5.3-1  | A<sub>0</sub> Requirements for Growth of Representative Microorganisms Cited in Compendial Chapters .......... 13 |
| Table 5.3-2  | A<sub>0</sub> and Limits (Threshold) for Microbial Growth Associated with Different Pharmaceutical Dosage Forms .......... 14 |
| Table 5.6-1  | Risk Analysis of Ingredients by Starting Material and Process Origin ........................................ 16 |
| Table 5.7-1  | Differences in Pharmacopoeia Log Reduction Acceptance Criteria by Product Type for Microbial Challenge Testing .......... 18 |
| Table 5.8.1-1| Applications of Different Resin Categories in Packaging ........................................ 23 |
| Table 6.4.2-1| Characteristics of Cleaning Agents .......... 30 |
| Table 7.1-1  | Summary of Microbial Testing Methods that May be Employed for Pharmaceutical Drug Products, Consumer Health Products, Medical Devices and Cosmetics .......... 33 |

| Table 7.4.1-1| Harmonized and Recommended Microbiological Quality Requirements for Nonsterile Drug Dosage Forms (Adapted from USP <1111>, 10) .......... 36 |
| Table 7.5-1  | Decision Matrix for Screening for Objectionable Microorganisms ............................... 41 |
| Table 8.3-1  | Major Outbreaks Associated with Contaminated Nonsterile Products in 1971-2011 ........................................ 46 |
| Table 8.3-2  | Most Significant Microorganisms Associated with the Ten Most Common Product Recalls, Major Outbreaks Related to Nonsterile Products and Nosocomial Infections .......... 48 |
| Table 8.5-1  | Microorganisms Usually Associated with Human Disease When Isolated from Clinical Specimens ........................................ 49 |
| Figure 9.3-1| Objectionable Microorganism Risk Decision Tree ........................................ 55 |